Difference Between CMP and Hepatic Panel
A Comprehensive Metabolic Panel (CMP) is a broader metabolic screening test that includes some liver markers along with kidney function, electrolytes, and proteins, while a hepatic (liver function) panel specifically focuses on liver-related enzymes and synthetic function markers to evaluate hepatic injury and disease.
What's Included in Each Panel
Comprehensive Metabolic Panel (CMP)
A CMP typically includes 14 tests covering multiple organ systems:
- Liver markers: ALT, AST, ALP, total bilirubin, albumin, total protein
- Kidney function: BUN, creatinine
- Electrolytes: sodium, potassium, chloride, carbon dioxide (bicarbonate)
- Glucose: blood sugar level
- Calcium: total calcium
Hepatic (Liver Function) Panel
According to British Society of Gastroenterology guidelines, an optimal liver blood test panel should include 1:
- Bilirubin (total and conjugated fractions)
- Albumin (synthetic function marker)
- ALT (alanine aminotransferase - hepatocellular injury marker)
- ALP (alkaline phosphatase - cholestatic marker)
- GGT (gamma-glutamyltransferase - increases sensitivity for liver disease)
- Full blood count (if not done within 12 months, to assess platelets)
Additional markers often included:
- AST (aspartate aminotransferase - for calculating AST:ALT ratio)
- PT/INR (prothrombin time - synthetic function)
- Total protein
Key Clinical Differences
Scope and Purpose
CMP: A general metabolic screening tool used for overall health assessment, monitoring chronic diseases, or evaluating generally unwell patients. It provides a snapshot of multiple organ systems but is not optimized specifically for liver disease detection 1.
Hepatic Panel: Specifically designed to detect, evaluate, and monitor liver disease. The inclusion of GGT significantly increases sensitivity for detecting liver pathology, though at the cost of some specificity 1.
Diagnostic Sensitivity for Liver Disease
The evidence shows important limitations of relying solely on standard panels:
ALT and ALP alone (as found in CMPs) identify the majority of adults with established liver disease, but this approach misses many patients with fatty liver disease (alcoholic and non-alcoholic), which account for 90% of liver mortality 1.
Adding GGT to the panel increases the likelihood of detecting abnormal liver tests from 15% to 30%, and elevated GGT is associated with increased liver-related and all-cause mortality 1.
AST is critical for calculating the AST:ALT ratio, where a ratio >1 indicates advanced fibrosis/cirrhosis. This ratio remains useful even when both values are within normal reference ranges 1.
Clinical Pitfalls and Caveats
Important limitations to understand:
Normal liver enzymes don't exclude cirrhosis: Both AST and ALT can be normal even in established cirrhosis, particularly in apoptotic diseases like fatty liver disease 1.
Albumin is not liver-specific: While albumin is only produced by the liver, low levels occur in sepsis, inflammatory disorders, nephrotic syndrome, malabsorption, and GI protein loss 1.
Bilirubin interpretation requires fractionation: Most isolated elevated bilirubin with predominantly unconjugated fraction is Gilbert's syndrome (benign), not liver disease 1.
Platelet count matters: Thrombocytopenia is the most common hematological abnormality in chronic liver disease and indicates advanced disease with portal hypertension 1.
When to Order Which Panel
Order a CMP when:
- Performing general health screening
- Monitoring chronic diseases (diabetes, hypertension)
- Evaluating acute illness with multi-system involvement
- Assessing electrolyte and kidney function alongside basic liver markers
Order a hepatic panel when:
- Specifically evaluating for liver disease
- Following up abnormal liver tests from a CMP
- Monitoring known liver disease
- Assessing patients with risk factors for liver disease (alcohol use, obesity, viral hepatitis risk)
- Evaluating right upper quadrant pain, jaundice, or hepatomegaly
Cost and Utilization Considerations
Research demonstrates that panel-based testing can lead to unnecessary test utilization. One study showed that implementing CMPs increased total calcium testing by more than 3-fold without changing the rate of calcium-related diagnoses 2. Similarly, the difference in cost between a basic metabolic panel (BMP) and CMP is approximately $21, with potential savings when targeted testing is used appropriately 3.
The key principle: Order the most specific panel for your clinical question. If you're screening for liver disease or following abnormal liver tests, a dedicated hepatic panel provides better diagnostic information than relying on the liver components of a CMP alone 1.